Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
The Journal of Clinical Investigation
|
March 1, 1994
Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors
C A Bondy, J Zhou, E Chin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 24, 2000
Insulin-like growth factor 1 regulates developing brain glucose metabolism
C M Cheng, R R Reinhardt, W H Lee, et al.
The Journal of Clinical Investigation
|
April 1, 1995
Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases
R R Reinhardt, E Chin, J Zhou, et al.
Diabetes, Obesity & Metabolism
|
September 30, 2014
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus
M Hompesch, A Jones-Leone, M C Carr, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2014
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
J Reusch, M W Stewart, C M Perkins, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 22, 1998
Biochemical and morphometric analyses show that myelination in the insulin-like growth factor 1 null brain is proportionate to its neuronal composition
C M Cheng, G Joncas, R R Reinhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
D Campos, J R Pereira, R R Reinhardt, et al.
The New England Journal of Medicine
|
January 23, 1999
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group
R M Navari, R R Reinhardt, R J Gralla, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2001
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
V Cocquyt, S Van Belle, R R Reinhardt, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
The Journal of Clinical Investigation
|
March 1, 1994
Cellular distribution of insulin-degrading enzyme gene expression. Comparison with insulin and insulin-like growth factor receptors
C A Bondy, J Zhou, E Chin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 24, 2000
Insulin-like growth factor 1 regulates developing brain glucose metabolism
C M Cheng, R R Reinhardt, W H Lee, et al.
The Journal of Clinical Investigation
|
April 1, 1995
Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases
R R Reinhardt, E Chin, J Zhou, et al.
Diabetes, Obesity & Metabolism
|
September 30, 2014
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus
M Hompesch, A Jones-Leone, M C Carr, et al.
Diabetes, Obesity & Metabolism
|
August 27, 2014
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
J Reusch, M W Stewart, C M Perkins, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience
|
July 22, 1998
Biochemical and morphometric analyses show that myelination in the insulin-like growth factor 1 null brain is proportionate to its neuronal composition
C M Cheng, G Joncas, R R Reinhardt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2001
Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone
D Campos, J R Pereira, R R Reinhardt, et al.
The New England Journal of Medicine
|
January 23, 1999
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group
R M Navari, R R Reinhardt, R J Gralla, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 21, 2001
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis
V Cocquyt, S Van Belle, R R Reinhardt, et al.
Page
of 2